Search results for: 'flow ad plan'

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

24 Aug 2021  |  North America  |  Market Research

US and EU Biotech Industry VC Investment Growth Opportunities

Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

Infographics

×

With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process developm...

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

19 Feb 2021  |  North America  |  Market Research

Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market

High Unmet Needs in Niche Oncology Indications will Drive Future Growth Potential

Infographics

×

Frost & Sullivans Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and c...

21 Aug 2020  |  Global  |  Market Research

Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024

Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities

Infographics

×

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new t...